- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 23.10. | As clinical trials rise globally, Europe's share of the pie has shrunk: IQVIA report | ||
| 23.10. | Boston Scientific posts 177% EP growth, pauses Farapulse study in first-line afib | ||
| 23.10. | Alpha-9 raises $175M series C to bankroll clinical-stage radiopharma pipeline | ||
| 23.10. | Roche culls cough candidate, pivots KRAS program after 'revaluing' entire pipeline | ||
| 23.10. | Ocuphire Pharma to transform into gene-therapy-focused biotech via Opus acquisition | ||
| 23.10. | Alto's midphase depression trial falls flat, raising doubts about pitch to disrupt neuropsychiatry R&D | ||
| 22.10. | GSK and Cambridge scientists join forces to fight immune-related kidney and lung diseases in $65M deal | ||
| 22.10. | It's official: Michelle Tarver named director of the FDA's devices center | ||
| 22.10. | Dotmatics debuts antibody engineering R&D software platform | ||
| 22.10. | Sangamo slashes time to market for Fabry gene therapy as FDA agrees to accelerated approval package | ||
| 22.10. | FDA grants de novo clearance to airway stent covered with human tissue | ||
| 22.10. | Otsuka's kidney disease drug improves UPCR levels in phase 3 trial | ||
| 22.10. | Minghui's thyroid eye disease drug slashes eye bulging in midstage trial | ||
| 22.10. | Roche tosses out tau prospect, returning rights to UCB 4 years after placing $120M bet | ||
| 22.10. | Rectify's new lead candidate improves bile composition, reduces inflammation in mice with liver disease | ||
| 22.10. | Editas strengthens in vivo gene therapy strategy via $238M LNP tech pact with Genevant | ||
| 21.10. | Horizon Surgical claims $30M for robotic, image-guided cataract surgery | ||
| 21.10. | Boston Scientific's navigation-equipped pulsed field ablation catheter passes FDA | ||
| 21.10. | Italy's Angelini pens $360M biobucks pact for Cureverse's phase 1 brain disorder drug | ||
| 21.10. | Vertex posts full pain data ahead of FDA ruling, unpacking combo results, Vicodin miss and stellar safety | ||
| 21.10. | Lykos accepts FDA's view that reviving rejected MDMA therapy's fortunes requires fresh phase 3 trial | ||
| 21.10. | Septerna plans $158M IPO to fund clinical readouts for GPCR pipeline | ||
| 21.10. | Seaport loads up $225M series B to continue Karuna veterans' voyage to clinical milestones | ||
| 21.10. | Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks, setting stage for pivotal program | ||
| 18.10. | Intuitive Surgical stock surges 10% amid da Vinci 5 demand, with full rollout set for 2025 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
